AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Naïve, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes. COMB157GUS10

July 15, 2022
https://clinicaltrials.gov/ct2/show/NCT05084638
Multiple Sclerosis
Principal Investigator: Helena Bulka, DO
Multiple Sclerosis
Accepting Participants
313-916-3501